Christopher Case, MD
Endocrinology, Diabetes & Metabolism · Jefferson City, MONPI 1871552794
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,886 of the $121,089 with a category attached, or 88.3%. Novo Nordisk accounts for 81.7% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $31,629 and has fallen 72.8% since, to $8,590 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $329.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$99K
- Bayer$15K
- Johnson & Johnson$5K
- Corcept Therapeutics$285
- Dexcom, Inc.$281
- Amgen$223
- plus $2K from 28 others
Across 750 payments — averaging $761.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$375K
- Novo Nordisk AS$142K
- Bayer$40K
- Amarin Pharma, Inc.$14K
What the payments were for
- Consulting fees$6,2255%
- Speaking & faculty fees$106,88688%
- Travel & lodging$3,5353%
- Food & beverage$4,3634%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 194 | $98,872 |
| Bayer | 18 | $15,033 |
| Johnson & Johnson | 11 | $4,866 |
| Corcept Therapeutics | 24 | $285 |
| Dexcom, Inc. | 23 | $281 |
| Amgen(2 entities) | 13 | $223 |
| Sanofi-aventis U.S. LLC | 5 | $162 |
| Abbott | 6 | $151 |
| Amarin Pharma, Inc. | 9 | $125 |
| Novartis | 6 | $123 |
| Lilly USA, LLC | 8 | $119 |
| Xeris Pharmaceuticals, Inc. | 6 | $110 |
| Radius Health, Inc. | 6 | $103 |
| AbbVie | 6 | $94 |
| Medtronic(2 entities) | 4 | $63 |
| IBSA Pharma Inc. | 2 | $50 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Tolmar, Inc. | 2 | $35 |
| Antares Pharma, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Pfizer | 1 | $29 |
| Insulet Corporation | 2 | $29 |
| AstraZeneca | 2 | $26 |
| Clarus Therapeutics Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Lifescan, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$121,089 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 724 | $1,218,769 |
| MounjaroTirzepatide | 433 | $556,418 |
| Tresiba Flextouch U-200Insulin Degludec | 345 | $429,332 |
| KorlymMifepristone | 17 | $340,709 |
| JardianceEmpagliflozin | 249 | $253,277 |
| FarxigaDapagliflozin Propanediol | 230 | $204,004 |
| Tresiba Flextouch U-100Insulin Degludec | 290 | $183,988 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 75 | $149,417 |
| RybelsusSemaglutide | 86 | $114,767 |
| Humalog Kwikpen U-100Insulin Lispro | 335 | $104,145 |
| TrulicityDulaglutide | 76 | $101,916 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $75,869 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 446 | $74,149 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 82 | $71,333 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 72 | $62,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba, Xultophy 100-3.6, Fiasp | $98,872 | $1,459,314912 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $119 | $682,148589 claims |
| Corcept TherapeuticsKorlym | $285 | $340,70917 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $31 | $291,172281 claims |
| AstraZenecaFarxiga, Byetta | $26 | $224,556253 claims |
| MerckJanuvia | $12 | $56,11967 claims |
| Johnson & JohnsonInvokana | $4,866 | $37,05236 claims |
| PfizerEliquis | $29 | $30,82434 claims |
| AmgenProlia | $223 | $27,81217 claims |
| BayerKerendia | $15,033 | $26,42827 claims |
| Sanofi-aventis U.S. LLCLantus | $162 | $12,28188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Jefferson City
- Alan RaubaJefferson City$594K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Adam MaghrabiBlue Springs$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.